Travere therapeutics CEO Eric Dube sells $25.4m in shares

Travere Therapeutics CEO Eric M. Dube sold a substantial amount of company shares, totaling approximately $25.4 million, during a three-day period from September 15 to September 17, 2026. Prior to selling, Dube exercised his employee stock options, acquiring 400,000 shares at an exercise price of $23.34 per share, amounting to $9.33 million.

He subsequently sold all 400,000 shares at prices ranging between $61.99 and $65.31 per share, close to the stock's 52-week high of $68.73. This sale appears to have been strategically timed, as the stock has increased by 168% over the past year, yet the current price suggests it may be overvalued. Dube's share sales were carried out according to a pre-established Rule 10b5-1 trading plan, approved on June 16, 2026.

In a separate report, Travere Therapeutics revealed robust financials for Q2 2026, with revenue exceeding $169.6 million, surpassing analysts' expectations of $160.66 million. This growth was largely fueled by the surge in FILSPARI sales, which rose by about 96% to $141.1 million. FILSPARI's sales now cover both IgA nephropathy and the recently introduced FSGS indication, marking the first complete quarter of availability for both conditions.

The second quarter marked the beginning of full-year revenue generation for FILSPARI, with U.S. net product sales reaching $161.4 million, primarily due to FILSPARI's sales. Stifel raised its price target for Travere Therapeutics to $62 from $43, maintaining a Hold rating after FILSPARI's successful launch in the FSGS market, which generated 2,012 start forms compared to 993 in the prior quarter.

The company also reported $8.2 million in licensing and collaboration revenue and concluded the quarter with approximately $489.2 million in cash, equivalents, and marketable securities. Management expressed optimism about FILSPARI's early uptake and noted favorable payer access progression.